Search

Bitolterol

Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

SNS-032

Indacaterol

It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.

Flotufolastat F-18

, and a high level of accumulation in tumors. … [A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive

Dezocine

Dezocine is a partial opiate drug and is used for pain management. … Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.

Trichlormethiazide

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

Phosphatidyl serine

PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. … PS has been shown to slow cognitive decline in animal models.

Etretinate

Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas. … Etretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid.

Cevimeline

It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. … Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

Artenimol

It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].